BioSpace News Archive

Small Pharma Inc. today confirms that the first patient has been dosed in its Phase I study comparing the profiles of intramuscular (“ IM ”) and intravenous (“ IV ”) , the Company’s proprietary formulation of N, N-dimethyltryptamine (“ DMT ”).

Cerevance today announced positive results from its Phase 1 study of CVN766 in healthy subjects.

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) today announced that the first patient has been dosed in the Phase 1 investigator sponsored clinical trial of VCN-01, an intravenous oncolytic adenovirus, for patients with high-grade brain tumors who are scheduled for surgical resection.

Alimera Sciences, Inc. today announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President and Chief Financial Officer (“CFO”), effective today, January 9, 2023.

PROCEPT® BioRobotics Corporation today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2022.

Daré Bioscience, Inc. today announced topline PK results from its Phase 1 / 2 clinical trial of DARE-HRT1 that support the potential of DARE-HRT1 as an effective hormone therapy (HT) based on the levels of hormones released.

TFF Pharmaceuticals, Inc. today announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer.

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today provided a corporate update, including its roadmap for 2023.

Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations.

Imbria Pharmaceuticals, Inc. today announced the enrollment of the first patient in Part 2 of the IMPROVE-DiCE Phase 2 clinical trial of ninerafaxstat in patients with heart failure with preserved ejection fraction (HFpEF).